Pre-eclampsia Flashcards

1
Q

Discuss hypertension in pregnancy
-Incidence of types of HTN/PET/Eclampsia (4)
-Definitions of
-HTN
-Severe HTN
-Chronic HTN

A
  1. Incidence
    -HTN 10-15%
    -PET 3-5%
    -Eclampsia 1% of all PET
    -Most common cause of iatrogenic prematurity
  2. Definitions
    HTN: Systolic BP >=140 OR diastolic >=90 as measured on 2 occasions 4 hrs apart Or BP >160/100 on a single occasion
    Severe HTN: = >170/110
    Chronic HTN: Prior to 20/40 or if persisting > 3 months PP
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Discuss chronic HTN noted in pregnancy
1. Definition (2)
2. Causes (4)
3. Investigations (4)
4. Risks for pregnancy (5)
5. Diagnosis of superimposed PET on chronic HTN (4)

A
  1. Definition
    HTN>140/90 before 20 weeks or persisting after 3months PP
  2. Causes
    -95% is due to idiopathic HTN (essential HTN). Need to rule out secondary causes before giving this dx
    -Renal causes: renal artery stenosis, CKD, DM, SLE
    -Cardiac causes: Coarctation of the aorta
    -Endocrine disorders: Phaeochromocytoma, Cushings, Conn’s, hyperparathyroidism
  3. Investigations
    -Check for end organ damage
    -Check baseline Cr and proteinuria
    -Echo
    -Renal screening
  4. Risk for pregnancy
    -Development of PET 25%, 46% if severe HTN
    -PTD 50% if superimposed PET
    -SGA - 48% if PET
    -CS - 70% if PET
    -Placental abruption
  5. Diagnosis of superimposed PET on chronic HTN
    -SGA in those with chronic HTN not diagnostic of PET
    -High suspicion if developing worse HTN
    -Look for other fetal effects of PET - oligo, abnormal dopplers, raised Uterine artery dopplers
    -If pre-existing proteinuria then other features must be present for diagnosis
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Discuss HTN in pregnancy
-Definition of gHTN
-Risk of developing PET if gHTN (2)
-Definition of PET (7)
-Definition of early onset PET (1)
-Definition of severe PET (6)

A
  1. Definition of PIH/gHTN
    New onset HTN >140/90 if >20/40 and resolves before 6/52 PP
  2. Risk of developing PET
    -If early onset gHTN (<30/40) risk = 40%
    -If late onset gHTN (>38/40) risk = 7% chance
  3. Definition of PET
    New onset of HTN >20/40 + end organ dysfunction
    End organ dysfunction:
    -Renal - Proteinuria: uPCR >30 / >300mg/day, Cr >90 Oligouria <80mL/4hrs
    (If underlying renal disease don’t use proteinuria)
    -Haematological - Plts<100, Haemolysis (LDH, Bili, Haptoglobin)
    -Liver -Epigastric pain, RUQ pain, Raised LFTs - >2x upper limit
    -Neurological - eclampsia, hypereflexia, persistent headache
    -Pulmonary oedema
    -IUGR
  4. Definition of early onset PET = <34/40
  5. Definition of severe PET
    No clear definition
    Difficulty controlling BP
    HELLP, worsening thrombocytopenia, impending eclampsia, worsening growth restriction
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Discuss eclampsia
-Definition
-Onset
-Risk factors (1)

A
  1. Definition
    -Tonic clonic seizure
    -Only 33% have dx of PET prior to seizure
  2. Timing
    -45% antinatal, 20% intrapartum, 35% postpartum
  3. Risk factors
    -3 x more common in teenagers
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Discuss the pathogenesis of PET (7 points)

A

PET is multifactorial illness
1. Genetic role
-Increased risk if family Hx
2. Immune factors
3. Abnormal placentation with spiral arteries remaining under high resistance due to poor cytotrophoblastic invasion
4. Systemic endothelial dysfunction
-Placental release of antiangiogenic factors such as sFlt1 and sENG result in vascular permeability
5. Exaggerated systemic inflammatory response with endothelial dysfunction with increased vascular tone and capillary permeability
6. Vasoconstriction from increased thromboxane
7. Increased sensitivity to angiotensin II leading to increased BP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Discuss PET
-Risk factors (8)
-Protective factors (4)

A
  1. Risk factors
    -BMI >30 RR 2
    -Family Hx RR 3
    -Age >40 RR 2
    -Primip RR 2-3
    -Multiple pregnancy RR 32
    -Previous PET RR 7
    -Pre-existing renal disease or HTN or APLS RR 10
    -Low AFP
    -Pre-existing diabetes RR 4
  2. Protective factors
    -Previous miscarriage to same father as current pregnancy
    -High fruit intake
    -Smoking but not if have chronic HTN
    -Taking >12 months to conceive
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Discuss screening for women with new onset HTN >20/40
-What to screen for
-Other markers of PET but not recommended

A
  1. What to screen
    -If onset HTN <20 weeks look for secondary causes
    -Urinalysis - send PCR if +1 protein on dipstick
    -FBC, U&E, Cr, LFT (Coags if platelets abnormal)
    -If concern for haemolysis - LDH, haptoglobin, bili, blood film
    -Regular GS LV and dopplers
    -If early onset PET look for underlying renal disease, SLE, ALPS
    -P1GF / sFlt1 ratio can be used for diagnosis. SOMANZ. Don’t use to time delivery. DOn’t use alone.
  2. Other markers
    -ADAM-12
    -Low PAPP-A
    -Uterine artery dopplers - high negative predictive value so useful in those at high risk
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Discuss ongoing investigations for women with HTN in pregnancy
-Chronic HTN
-gHTN
-PET

A
  1. Chronic HTN - each visit:
    -Assess BP, sx of PET, fetal wellbeing
    -Proteinuria
    -PET bloods if new proteinuria or sudden increase in BP
  2. gHTN
    -Assess BP, sx of PET, fetal wellbeing
    -Proteinuria 1-2 x weekly
    -PET bloods weekly
  3. PET
    -Assess BP, sx of PET, fetal wellbeing
    -Assess proteinuria and if not proteinuria continue daily
    -2 x weekly PET bloods or more frequently if unstable
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Discuss treatment of HTN (6 general points)

A

-Treatment of HTN is the same regardless of underlying pathology
-Treatment allows prolongation of pregnancy but doesn’t treat underlying pathology
-MAP >150 is associated with loss of cerebral autoregulation and increased risk of stroke
-If BP is >160/110 treatment is mandatory
-Aim 135/80 for BP control. CHIPS and CHAPS study. No neonatal difference but better maternal outcmes with better control
-Definitive treatment is delivery

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Discuss treatment meds for HTN
-First line treatments (3), second line (2) third line (1)
-Max dose
-Mechanism of action
-Contra-indications

A
  1. First line treatments
    Labetalol
    -Max dose 2.4g/24hrs 400mg Q4H
    -MOA: Alpha and beta adrenergic blocker
    -Caution with asthma, COPD
    Nifedipine
    -40mg PO BD
    -MOA: Calcium channel blocker
    -Caution with cardiac disease, aortic stenosis
    Methyldopa
    -Max dose 1g TDS
    -MOA: Unclear but acts centrally
    -Caution: depression, liver disease, OK in cardiac and renal conditions
  2. Second line
    Hydralazine
    -Max dose 75mg QID
    -MOA: Peripheral vasodilator through smooth muscle relaxation
    -Avoid in SLE
    Prazosin
    Max dose 5mg TDS
    MOA: Alpha adrenergic blocker
  3. Third line
    Metoprolol
    -Max dose 95mg BD
    -MOA: Beta adrenergic blocker
    -Caution in asthma, safety for fetus not established
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Discuss USS frequency and timing in women with HTN in pregnancy
-Chronic HTN
-GHTN
-PET
-PET with FGR

A
  1. Chronic HTN
    -Early dating USS
    -GS + LV and doppler from third trimester with frequency as indicated
  2. gHTN
    -GS + LV and doppler 3-4 weekly from time of diagnosis
  3. PET
    -GS + LV and doppler 2-3 weekly from time of diagnosis
    -CTG twice weekly or more if indicated
  4. PET with FGR
    -CTG 2 x weekly
    -GS every 2 weeks
    -LV and doppler weekly or more frequently depending on dopplers and LV
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Discuss timing of delivery
-Early onset < 24weeks
-If 24-34
-If >34
-If >37
-If HTN but no PET

A
  1. If <24/40
    -Discuss TOP. Maternal morbidity 70%, perinatal mortality 80%
  2. If <34
    -Give steroids +/- MgSO4 and aim to deliver 48 hrs after this
    -Transfer to tertiary institution
    -Aim to prolong pregnancy. Leads to increased maternal morbidity - Increased risk severe morbidity = 25-41%
  3. > 34
    -Aim to prolong pregnancy
    -Steroids if <35/40
  4. If >37
    -Deliver
  5. If HTN but no PET can deliver between 37-39 weeks
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the indications for immediate delivery (within 48hrs) (11)

A

-Gestational age >37/40
-Inability to control HTN
-Deteriorating plt count
-Deteriorating LFTs
-Deteriorating renal function BUT not worsening proteinuria
-Placental abruption
-Eclampsia
-Persistent epigastric pain with N&V and abnormal LFTs
-Acute pulmonary oedema
-Severe fetal growth restriction
-Non-reassuring trace
-HELLP - 6% mortality with expectant management

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Discuss management of severe PET
-Where to manage
-Who to involve
-Control of BP (3)
-Control of fluid (3)
-Fetal considerations (3)
-Other considerations (5)

A
  1. Manage in HDU or DS
  2. Involve anaesthetics, paeds, senior obstetrics
  3. Control BP
    -Labetalol 20mg IV over 2 mins repeat in 10 mins continue until BP < 160/110. Max dose 80mg
    -Hydralazine 10mg IV over 3-10mins repeat every 20 mins if BP >160/110 max dose 30mg. Give 250mL fluid bolus first
    -Nifedipine 5-10mg FA with 10-20mg LA simultaneously. Repeat in 45mins if BP > 160/110. Max dose 40mg
  4. Manage fluid
    -Maintenance - 80mL/hr
    -Fluid balance
    -If oligouric 300mL fluid challenge
  5. Fetal considerations
    -Monitor with CTG
    -Consider steriods
    -Consider MgSO4
  6. Other considerations
    -Consider MgSO4 - 50% reduction in eclampsia
    -Consider VTE / SCD or TEDS if CS imminent and LMWH postnatal
    -Continuous saturation monitoring
    -Plan delivery
    -Bloods - check plts twice daily if <100 + coags
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Discuss management of eclampsia
-Immediate response (6)
-Medications (5)
-Other considerations (6)

A
  1. Immediate response
    -Position safely
    -Monitor fetus
    -Oxygen + support airway
    -IV access
    -Call for help
    -Sats probe
  2. Medications
    -4g MgSO4 over 20mins then 1g/hr infusion
    -If further seizure give another 2g
    -If prolonged seizure and can’t give MgSO4 can give IV diazepam 2mg/min for max of 10mg or clonazepam 1-2mg over 2-5 mins
    -Monitor Mg levels - therapeutic dose 2-4 - if renal impairment
    -Give half maintenance dose if AKI
    -Continue for24hrs after last seizure
  3. Other considerations
    -Control BP to reduce risk of further seizures
    -Monitor urine output, sats, BP, tendon reflexes, resp rate
    -If for delivery consider mode
    -If anaesthesia - regional better than GA as increased BP
    -If PPH avoid ergo
    -Postnatal meds - avoid tramadol, NSAIDS, Ketamine
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Discuss considerations for future in those with PET/HTN
-Risk of developing PET in future pregnancies (3)
-Risk of developing health conditions for mother (4)
-Prevention strategies for future pregnancies (3)
-Recommended screening (2)

A
  1. Risk of developing PET in future pregnancies
    -15% chance of recurrence
    -Increased risk if early onset (40% chance if onset 20-28 weeks)
    -Increased risk if underlying health condition
  2. Risk of developing health conditions
    -HTN 3-4 fold
    -IHD 2 fold
    -Cerebrovascular disease - 2 fold
    -ESRD 4 fold
  3. Prevention strategies
    -Aspirin 100mg before 16 weeks 18% reduction in PET
    -Calcium 1g (2g if low intake) 50% reduction of PET in high risk women
    -Vit D if low - not routinely recommended
  4. Recommended screening
    -BP yearly
    -Yearly lipids and glucose
17
Q

Discuss thromboprophylaxis in PET (3)

A
  1. Screen for VTE risk
  2. PET is considered a major risk for VTE
  3. If 2 major risk factors or 1 major and 2 minor factors then give VTE prophylaxis
18
Q

Discuss the HYPITAT trial
-Aim (1)
-Study design (2)
-Primary outcome (1)
-Secondary outcomes (2)

A
  1. Aim
    -Whether IOL in women with mild PET or gHTN reduces severe maternal morbidity
  2. Study design
    -Open label RCT of EM vs IOL from 36/40
    -Conducted in 36 hospitals in Netherlands
  3. Primary outcome
    -Composite measure of maternal morbidity (Eclampsia, severe PET, HELLP, PE, abruption, PPH)
  4. Secondary outcomes
    -MOD
    -Neonatal morbidity and mortality (Composite measure)
19
Q

Discuss the HYPITAT trial
-Number included in study
-Results

A
  1. Number included in the study
    -750 in 2 equal groups
  2. Results
    -Less maternal morbidity (Mostly progression to severe disease) in the IOL group OR 0.71 31% vs 44% (SS) NNT 8
    -Less antihypertensive use in IOL group
    -No difference in CS rates
    -Neonatal outcomes same in both groups
    -Sub group analysis found the benefits of IOL did not extend to women with <37/40
20
Q

Discuss the CLASP trial
-Aim (1)
-Study design (2)
-Primary outcomes (3)
-Secondary outcomes (3)

A
  1. Aim
    -To determine if LDA reduces the incidence of PET
  2. Study design
    -RCT - placebo controlled
    -Included women 12-32 weeks with increased risk of PET/IUGR signs or Sx of PET/IUGR
  3. Primary outcome
    -Development of proteinuria PET
    -Still birth and neonatal death secondary to PET/HTN/IUGR
    -IUGR <3%
  4. Secondary outcomes
    -Timing of delivery (PTB)
    -Neonatal haemorrhage
    -Maternal haemorrhage
21
Q

Discuss the CLASP trial
-Number recruited to the study (1)
-Primary outcome results (4)
-Secondary outcome results (4)

A
  1. Number recruited to the study
    -9000
  2. Primary outcomes
    -6.7% on aspirin and 7.6% on placebo developed PET. 12% odds reduction (NS)
    -Biggest effect seen in women commenced before 20/40 (22% reduction NS)
    -No impact if started prophylactically or theraputically
    -No impact on IUGR between groups
  3. Secondary results
    -17% vs 19% PTD (before 37/40) if on aspirin cf placebo 12% Odds reduction (SS) if started prophylactically. 2 fewer deliveries per 100
    -20 vs 22% PTD if on aspirin cf placebo 21% Odds reduction (SS) if started for treatment. 5 fewer deliveries per 100
    -Fewer PTD did not correspond to better survival rates in the aspirin group
    -No difference in maternal or fetal haemorrhage
22
Q

Discuss the MAGPIE study
-Aim (1)
-Study design (4)
-Primary outcomes (2)
-Secondary outcomes (4)

A
  1. Aim
    To see if women with PET or their children do better if given MgSO4 cf placebo
  2. Study design
    -RCT in 33 countries
    -Randomised to placebo vs MgSO4
    -Rx given prior to delivery or within 24hrs PP
    -Included if clinical uncertainty about MgSO4
  3. Primary outcomes
    -Eclampsia
    -Fetal demise if randomised prior to birth
  4. Secondary outcomes
    -Maternal morbidity
    -MgSO4 toxicity
    -Other MgSO4 SE
    -Complications of birth and delivery
    -Neonatal morbidity
23
Q

Discuss the MAGPIE trial
-Number included in the study
-Results of primary outcomes (3)
-Results of secondary outcomes (4)

A
  1. Number included in the study
    10 000
  2. Results of primary outcomes
    -Reduced eclampsia in treatment group 0.8 vs 1.9% (58% risk reduction, 11 fewer per 1000, RR 0.42 SS NNT 91)
    -MgSO4 reduced eclampsia in severe and nn-severe PET
    -No difference in neonatal mortality between groups
  3. Results of secondary outcomes
    -Increased SE in MgSO4 group 24% vs 5%
    -Less placental abruption in the treatment group (RR 0.7 SS)
    -No difference in maternal morbidity between groups
    -Less maternal mortality in MgSO4 group but NS